<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04199078</url>
  </required_header>
  <id_info>
    <org_study_id>PALOMA II</org_study_id>
    <nct_id>NCT04199078</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Explore Papilocare Gel Efficacy to Repair of the Cervico-vaginal Mucosa With HPV High Risk Lesions.</brief_title>
  <acronym>PALOMA2</acronym>
  <official_title>Ensayo clínico Aleatorizado, Abierto, Paralelo, Controlado, multicéntrico, Para Explorar la Eficacia Del Gel Vaginal Papilocare® en la reparación de la Mucosa Cervical Con Lesiones Causadas Por Virus Papiloma Humano de Alto Riesgo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Procare Health Iberia S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Adknoma Health Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Procare Health Iberia S.L.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II, exploratory, randomized, open, controlled and parallel groups clinical trial to&#xD;
      evaluate the effectiveness of exploratory gel Papilocare in the repair of the cervico-vaginal&#xD;
      mucosa with lesions caused by HPV-HR. All the patients included in the study will be&#xD;
      randomized (1:1:1:1) in 4 arms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase II, exploratory, randomized, open, controlled and parallel groups clinical trial to&#xD;
      evaluate the effectiveness of exploratory gel Papilocare in the repair of the cervico-vaginal&#xD;
      mucosa with lesions caused by HPV-HR. All the patients included in the study will be&#xD;
      randomized (1:1:1:1) to Arm A (Papilocare schedule A), Arm B (Papilocare schedule B) and Arm&#xD;
      C (Papilocare schedule C) Arm D (usual clinical practice-without treatment-).&#xD;
&#xD;
      Selection period of 1 month, followed by randomization and 6 months of treatment followed by&#xD;
      a period of another 6 months without treatment.&#xD;
&#xD;
      Patients will visit the site into a total of 5 visits throughout the study. Total study&#xD;
      duration: 13 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 25, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the repairment of the cervico-vaginal mucosa with concordant colposcopic image</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate the repairment of the cervico-vaginal mucosa in positive high risk HPV women with a cytological result of squamous atypia of undetermined significance (ASC-US) or low-grade squamous lesion (LSIL) or glandular atypia of undetermined significance (AG-US), with concordant colposcopic image, 6 months after the start of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the repairment of the cervico-vaginal mucosa with concordant colposcopic image</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>Evaluate the repairment of the cervico-vaginal mucosa in positive high risk HPV women with a cytological result of squamous atypia of undetermined significance (ASC-US) or low-grade squamous lesion (LSIL) or glandular atypia of undetermined significance (AG-US), with concordant colposcopic image at 3 and 12 months after the start of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of reeptielization degree of the cervico-vaginal mucosa by a likert-type scale</measure>
    <time_frame>3,6 and 12 months</time_frame>
    <description>A likert-type scale will be used to evaluate the reeptielization degree of the cervico-vaginal mucosa at 3, 6 and 12 months after the start of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of HPV at 6 and 12 months after starting treatment.</measure>
    <time_frame>6 and 12 months]</time_frame>
    <description>Percentage of patients with total and partial clearance of HPV measured by genotyping PCR at 6 and 12 months after starting treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of vaginal health status by vaginal health index score (Bachmann)</measure>
    <time_frame>3,6 and 12 months]</time_frame>
    <description>The vaginal health index score (Bachmann) will be used to evaluate vaginal health status at 3, 6 and 12 months from the start of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of Papilocare® gel during the 6 months of treatment and 6 months of follow-up.</measure>
    <time_frame>6 and 12 months]</time_frame>
    <description>Safety and tolerability: incidence, nature and severity of adverse events at 6 months of treatment and 6 months of follow-up period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the stress received from the patients at 3, 6 and 12 months after starting treatment.</measure>
    <time_frame>3,6 and 12 months]</time_frame>
    <description>The stress will be assessed on the PSS14 scale (Perceived Stress Scale 14 items) at 3, 6 and 12 months after the starting treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the satisfaction of papilocare gel use by a likert-type scale</measure>
    <time_frame>3 and 6 months]</time_frame>
    <description>A likert-type scale will be used to evaluate the satisfaction of papilocare gel use by the patients at 3 and 6 months after the start of treat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with good therapeutic compliance</measure>
    <time_frame>3 and 6 months]</time_frame>
    <description>Percentage of patients with good adherence to the treatment will be used to evaluate the therapeutic compliance at 3 and 6 months after the start of treatment.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">288</enrollment>
  <condition>Human Papilloma Virus</condition>
  <condition>Human Papilloma Virus Infection</condition>
  <condition>Cervix Lesion</condition>
  <arm_group>
    <arm_group_label>A - papilocare alternative days treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A: scheme A (21 days / 1 cannula per day + 7 days rest) x 1 month + alternate days up to 6 months (except for menstruation days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B - papilocare semiintensive treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B: scheme B (21 days / 1 cannula per day + 7 days rest) x 3 months + alternate days up to 6 months (except menstruation days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C - papilocare intensive treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm C: scheme C (21 days / 1 cannula per day + 7 days rest) x 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D - standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Arm D: usual clinical practice - no treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Papilocare vaginal gel</intervention_name>
    <description>Papilocare is a gel vaginally administered by a singledose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution</description>
    <arm_group_label>A - papilocare alternative days treatment</arm_group_label>
    <arm_group_label>B - papilocare semiintensive treatment</arm_group_label>
    <arm_group_label>C - papilocare intensive treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Woman between the ages of 30 and 65 (both inclusive).&#xD;
&#xD;
          2. Able to read and understand the Patient Information Sheet and the Informed Consent&#xD;
             form.&#xD;
&#xD;
          3. Acceptance in the participation of the essay and signature of the Informed Consent&#xD;
             form.&#xD;
&#xD;
          4. ASC-US or LSIL or AG-US cytological result (maximum 3 months prior to inclusion) with&#xD;
             concordant colposcopic image (performed at the screening visit).&#xD;
&#xD;
          5. High risk HPV positive by PCR performed at screening visit.&#xD;
&#xD;
          6. Is able, at the discretion of the researcher, to comply with the requirements of the&#xD;
             trial and without hindrance to follow the instructions and assessments throughout it.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically relevant immune system alterations, or any other autoimmune disease or in&#xD;
             treatment with immunosuppressants.&#xD;
&#xD;
          2. Non-diagnosed abnormal genital hemorrhage (during the 6 months prior to the screening&#xD;
             visit).&#xD;
&#xD;
          3. To had been vaccinated against HPV.&#xD;
&#xD;
          4. Other symptomatic vulvovaginal infections.&#xD;
&#xD;
          5. Surgical cervical excision in the last year or total hysterectomy.&#xD;
&#xD;
          6. Previous history of gynecological cancer.&#xD;
&#xD;
          7. Participation in any other clinical trial at present or in the 4 weeks prior to the&#xD;
             inclusion of the trial.&#xD;
&#xD;
          8. Any planned surgery that prevents the correct compliance with the guidelines.&#xD;
&#xD;
          9. Use of vaginal contraceptives or other vaginal hormonal treatments.&#xD;
&#xD;
         10. Contraindications for the use of Papilocare® gel or known allergies to any of its&#xD;
             components.&#xD;
&#xD;
         11. Women of childbearing age who do not use effective contraceptive methods, pregnant&#xD;
             women, with suspicion of pregnancy or woman who are breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Cortes Bordoy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AEPCC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Josep Combalia, MD</last_name>
    <phone>+34 936455441</phone>
    <email>combalia.j@procarehelath.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital U. de Donostia</name>
      <address>
        <city>Donostia</city>
        <state>Guipuzcoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arantxa Leukona</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Puerta del Sur</name>
      <address>
        <city>Móstoles</city>
        <state>Madrid</state>
        <zip>28938</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Angel Zambrano</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Mallorca</state>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Ruiz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Nuestra Señora de Candelaria</name>
      <address>
        <city>Santa Cruz De Tenerife</city>
        <state>Tenerife</state>
        <zip>38010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfonso Quesada</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Antonio López</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Torrecárdenas</name>
      <address>
        <city>Almeria</city>
        <zip>04009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriel Fiol, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gemma Mancebo, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Josep Maria Solé, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d' Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M Cristina Centeno</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Basurto</name>
      <address>
        <city>Bilbao</city>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igancio Lobo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. U. Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Angel Montserrat</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Angeles Calderón</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Assir Hospitalet de Llobregat</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <zip>08904</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margarita Riera, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Belén López</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Manacor</name>
      <address>
        <city>Manacor</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Agüera, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. General Universitario Santa Lucía</name>
      <address>
        <city>Murcia</city>
        <zip>30202</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paloma Ortega</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. R. U. de Málaga / Materno Infantil</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesús S. Jiménez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inmaculada Rodríguez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Gurrea, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Álvaro Cunqueiro</name>
      <address>
        <city>Vigo</city>
        <zip>36312</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Orlando Valenzuela, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 11, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillomavirus Infections</mesh_term>
    <mesh_term>Papilloma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The PIs from the participant sites gonna received the study protocol and the informed consent form previously to the initiation of the study and every time it occurs an amendment over the protocol, ICF or any other study document. Once the study has finished and the data has been analyzed, the PI's from the sites gonna received the CSR.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

